B. Guérette

2.2k total citations
60 papers, 1.8k citations indexed

About

B. Guérette is a scholar working on Rheumatology, Molecular Biology and Hematology. According to data from OpenAlex, B. Guérette has authored 60 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Rheumatology, 18 papers in Molecular Biology and 14 papers in Hematology. Recurrent topics in B. Guérette's work include Rheumatoid Arthritis Research and Therapies (23 papers), Spondyloarthritis Studies and Treatments (16 papers) and Muscle Physiology and Disorders (14 papers). B. Guérette is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (23 papers), Spondyloarthritis Studies and Treatments (16 papers) and Muscle Physiology and Disorders (14 papers). B. Guérette collaborates with scholars based in Canada, United States and United Kingdom. B. Guérette's co-authors include Jacques P. Tremblay, Raynald Roy, Jean‐Thomas Vilquin, Isabelle Asselin, Ikuo Kinoshita, Arthur Kavanaugh, H. Küpper, Roy Fleischmann, Paul Emery and Laura Redden and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

B. Guérette

58 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Guérette Canada 21 821 641 455 409 361 60 1.8k
Jordi Barquinero Spain 22 625 0.8× 892 1.4× 115 0.3× 286 0.7× 524 1.5× 58 2.0k
Ann Traynor United States 26 401 0.5× 432 0.7× 381 0.8× 582 1.4× 298 0.8× 63 2.1k
Francine Mugneret France 25 902 1.1× 238 0.4× 352 0.8× 190 0.5× 416 1.2× 81 2.5k
C.A. Griffin United States 21 795 1.0× 327 0.5× 308 0.7× 190 0.5× 267 0.7× 41 2.1k
François Cornélis France 29 422 0.5× 877 1.4× 138 0.3× 685 1.7× 311 0.9× 62 1.8k
Myrtle Y. Gordon United Kingdom 22 914 1.1× 241 0.4× 612 1.3× 511 1.2× 204 0.6× 60 2.3k
Zhigui Ma China 22 991 1.2× 639 1.0× 166 0.4× 132 0.3× 80 0.2× 56 2.5k
Marie‐Caroline Le Bousse‐Kerdilès France 32 1.1k 1.4× 621 1.0× 1.5k 3.4× 606 1.5× 162 0.4× 82 3.1k
Michaela Nathrath Germany 24 689 0.8× 215 0.3× 125 0.3× 236 0.6× 218 0.6× 70 1.8k
M Błaszczyk Poland 25 294 0.4× 733 1.1× 180 0.4× 307 0.8× 209 0.6× 87 2.0k

Countries citing papers authored by B. Guérette

Since Specialization
Citations

This map shows the geographic impact of B. Guérette's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Guérette with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Guérette more than expected).

Fields of papers citing papers by B. Guérette

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Guérette. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Guérette. The network helps show where B. Guérette may publish in the future.

Co-authorship network of co-authors of B. Guérette

This figure shows the co-authorship network connecting the top 25 collaborators of B. Guérette. A scholar is included among the top collaborators of B. Guérette based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Guérette. B. Guérette is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ogdie, Alexis, Mei Liu, Leslie R. Harrold, et al.. (2020). Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results. The Journal of Rheumatology. 48(5). 693–697. 9 indexed citations
2.
Mease, Philip J., Dafna D. Gladman, Alexis Ogdie, et al.. (2020). Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. Arthritis Care & Research. 72(6). 814–821. 7 indexed citations
3.
Kavanaugh, Arthur, Dafna D. Gladman, Christopher J Edwards, et al.. (2019). Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis. Arthritis Research & Therapy. 21(1). 118–118. 57 indexed citations
4.
Mease, Philip J., Elliot D. Rosenstein, Feng Huang, et al.. (2018). SAT0347 Baseline characteristics of patients with psoriatic arthritis initiated on apremilast in the corrona psoriatic arthritis/spondyloarthritis (PSA/SPA) registry. Annals of the Rheumatic Diseases. 77. 1039–1039. 1 indexed citations
5.
Mease, Philip J., Dafna D. Gladman, Arthur Kavanaugh, et al.. (2017). Characterization of Clinical Benefits in Subjects Classified As ACR20 Non-Responders at Week 104 of Apremilast Treatment: Subanalysis of 3 Long-Term, Phase III Trials. Queensland's institutional digital repository (The University of Queensland). 69. 864–865. 1 indexed citations
6.
Landewé, Robert, Josef S Smolen, S. Florentinus, et al.. (2015). Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. Arthritis Research & Therapy. 17(1). 133–133. 11 indexed citations
8.
Keystone, Edward, Boulos Haraoui, B. Guérette, et al.. (2013). Clinical, Functional, and Radiographic Implications of Time to Treatment Response in Patients With Early Rheumatoid Arthritis: a Posthoc Analysis of the PREMIER Study. The Journal of Rheumatology. 41(2). 235–243. 16 indexed citations
9.
Landewé, R., Edward Keystone, Smolen Js, et al.. (2011). DISCONNECT BETWEEN DISEASE ACTIVITY AND JOINT SPACE NARROWING FOR PATIENTS WITH EARLY RA TREATED WITH ADALIMUMAB PLUS METHOTREXATE BUT NOT METHOTREXATE ALONE: CASE FOR ANTI-TNF CARTILAGE PROTECTION. Lara D. Veeken. 50. 113–113. 2 indexed citations
10.
Breedveld, F. C., Edward Keystone, D. van der Heijde, et al.. (2011). Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial. Data Archiving and Networked Services (DANS). 63(10). 118–119. 5 indexed citations
11.
Keystone, Edward, D. van der Heijde, M. Weinblatt, et al.. (2011). Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes in Patients with Advanced Rheumatoid Arthritis: Analysis of the Final 10-Year Results of An Open-Label Extension of a Phase 3 Trial. Data Archiving and Networked Services (DANS). 63(10). 1 indexed citations
12.
Haraoui, Boulos, Alfred Cividino, Jacqueline Stewart, B. Guérette, & Edward Keystone. (2011). Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study. BMC Musculoskeletal Disorders. 12(1). 261–261. 10 indexed citations
13.
Schneider, Helga, B. Guérette, Christine Guntermann, & Christopher E. Rudd. (2000). Resting Lymphocyte Kinase (Rlk/Txk) Targets Lymphoid Adaptor SLP-76 in the Cooperative Activation of Interleukin-2 Transcription in T-cells. Journal of Biological Chemistry. 275(6). 3835–3840. 53 indexed citations
14.
Vilquin, Jean‐Thomas, B. Guérette, Jack Puymirat, et al.. (1999). Myoblast transplantations lead to the expression of the laminin α2 chain in normal and dystrophic (dy/dy) mouse muscles. Gene Therapy. 6(5). 792–800. 24 indexed citations
15.
Guérette, B., K Wood, Raynald Roy, & Jacques P. Tremblay. (1997). Efficient myoblast transplantation in mice immunosuppressed with monoclonal antibodies and CTLA4 Ig. Transplantation Proceedings. 29(4). 1932–1934. 8 indexed citations
16.
Guérette, B., et al.. (1996). Prevention of Immune Reactions Triggered by First-Generation Adenoviral Vectors by Monoclonal Antibodies and CTLA4Ig. Human Gene Therapy. 7(12). 1455–1463. 49 indexed citations
17.
Vilquin, Jean‐Thomas, B. Guérette, Ikuo Kinoshita, et al.. (1995). FK506 Immunosuppression to Control the Immune Reactions Triggered by First-Generation Adenovirus-Mediated Gene Transfer. Human Gene Therapy. 6(11). 1391–1401. 138 indexed citations
18.
Asselin, Isabelle, Martine Tremblay, Jean‐Thomas Vilquin, et al.. (1995). Quantification of normal dystrophin mRNA following myoblast transplantation in mdx mice. Muscle & Nerve. 18(9). 980–986. 17 indexed citations
19.
Kinoshita, Ikuo, Jean‐Thomas Vilquin, B. Guérette, et al.. (1994). Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle & Nerve. 17(12). 1407–1415. 154 indexed citations
20.
Huard, Johnny, et al.. (1994). Human myoblast transplantation in immunodeficient and immunosuppressed mice: Evidence of rejection. Muscle & Nerve. 17(2). 224–234. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026